Carteolol en es it fr

Carteolol Brand names, Carteolol Analogs

Carteolol Brand Names Mixture

  • No information avaliable

Carteolol Chemical_Formula


Carteolol RX_link

Carteolol fda sheet

Carteolol msds (material safety sheet)

Carteolol Synthesis Reference

No information avaliable

Carteolol Molecular Weight

292.373 g/mol

Carteolol Melting Point

No information avaliable

Carteolol H2O Solubility

No information avaliable

Carteolol State


Carteolol LogP


Carteolol Dosage Forms

Ophthalmic Solution (1%)

Carteolol Indication

For the treatment of intraocular hypertension and chronic open-angle glaucoma

Carteolol Pharmacology

Carteolol is a beta1 and beta2 (non-selective) adrenergic receptor-blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Carteolol, when applied topically to the eye, has the action of reducing elevated, as well as normal, intraocular pressure, whether or not accompanied by glaucoma. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss and optic nerve damage. Carteolol reduces intraocular pressure with little or no effect on pupil size or accommodation in contrast to the miosis which cholinergic agents are known to produce.

Carteolol Absorption

No information avaliable

Carteolol side effects and Toxicity

The most common effects expected with overdosage of a beta-adrenergic blocking agent are bradycardia, bronchospasm, congestive heart failure and hypotension.

Carteolol Patient Information

No information avaliable

Carteolol Organisms Affected

Humans and other mammals